GlassScriptPhysician profile
Nicole C Clark
NPI 1083110225
$3,528.01
in general payments reported to CMS, 2019-2025
34 companies · $761 in 2025
The $761 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $636 · 2023: $1,177 · 2024: $800 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,082.00 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $367.09 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $247.71 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $210.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $208.30 | 2022-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $143.13 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $131.98 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.72 | 2022-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $115.62 | 2022-2025 | Gardasil 9, Capvaxive, Belsomra |
| Janssen Pharmaceuticals, INC | $95.76 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $89.03 | 2023-2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $82.93 | 2022-2023 | |
| Lundbeck LLC | $59.08 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $55.70 | 2022-2023 | Quviviq |
| Medtronic, INC. | $52.57 | 2025 | Intellis Adaptivestim |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $48.41 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $46.41 | 2021-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $46.16 | 2022 | |
| Xeris Pharmaceuticals, INC. | $34.16 | 2022-2025 | Keveyis |
| Novartis Pharmaceuticals Corporation | $31.30 | 2021-2024 | |
| Edwards Lifesciences Corporation | $29.61 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astellas Pharma US INC | $28.73 | 2025 | Veozah |
| Azurity Pharmaceuticals, INC. | $20.08 | 2024 | Edarbi |
| Verona Pharma, INC. | $20.06 | 2025 | Ohtuvayre |
| Pfizer INC. | $19.34 | 2023 | |
| Corium, LLC | $19.21 | 2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $18.36 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $17.11 | 2023 | Exparel |
| Radius Health, INC. | $16.39 | 2024 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.44 | 2025 | Caplyta |
| Mylan Specialty L.P. | $15.06 | 2024 | Yupelri |
| Shield Therapeutics INC | $13.85 | 2024 | |
| Axsome Therapeutics, INC. | $13.60 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.